Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70038 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Annaswamy Raji und 11 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Fatty Liver, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Abstract (Originalsprache)
Background
Fibroblast growth factor 21 (FGF21) is a metabolic regulator with demonstrated efficacy for the treatment of metabolic dysfunction‐associated steatohepatitis (MASH). FGF21 signals through ‘c’ isoforms of the FGF receptors (FGFR) 1–3 and the co‐receptor β‐klotho.
Aims
We report the safety and efficacy of MK‐3655, a monoclonal antibody that binds β‐klotho and selectively activates the FGFR1c/β‐klotho co‐receptor complex, in patients with pre‐cirrhotic MASH.
Methods
Phase 2b, randomised, multicenter, double‐blind, placebo‐controlled, parallel‐group study in patients with pre‐cirrhotic MASH (NAS ≥ 4 and MASH CRN fibrosis score Stage 2 or 3). Participants were randomised 1:1:1:1 to receive MK‐3655 50 mg, 100 mg, 300 mg, or matching placebo subcutaneously every 4 weeks. The primary endpoint was MASH resolution without worsening of fibrosis by histology at Week 52. An interim analysis (IA) of liver fat content (LFC) was planned once ≥ 25 participants per treatment group completed an MRI‐PDFF assessment at Week 24.
Results
Among 183 participants, mean BMI was 33.4 kg/m 2 , mean LFC was 18.1%, and 52.5% had type 2 diabetes. At the IA, the differences from placebo in relative reduction from baseline in LFC were assessed as insufficient for continuation of the trial. Among participants with Week 24 LFC assessment, percent relative reductions from baseline (LS mean difference vs. placebo) for MK‐3655 50 mg ( N = 33), 100 mg ( N = 36), and 300 mg ( N = 31), were 19.1%, 19.0%, and 26.1%, respectively. MK‐3655 was generally well tolerated.
Conclusions
In patients with pre‐cirrhotic MASH, treatment with MK‐3655 resulted in a modest reduction in LFC at 24 weeks. Clinical Trial Number EudraCT: 2019‐003048‐63; NCT: 04583423.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, New Jersey, USA.
ORCID-Profile: Annaswamy Raji
Förderung
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Zitieren
APA
Raji, A., Gantz, I., Crutchlow, M., Flynn, H., Xu, L., Rodgers, A. J., Krishnan, R., Rizk, M. L., Hu, S., Kaufman, K. D., Engel, S. S., & MK‐3655 P001 Study Group (2025). Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70038
Vancouver
Raji A, Gantz I, Crutchlow M, Flynn H, Xu L, Rodgers AJ, et al. Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70038
BibTeX
@article{Raji2025,
author = {Raji, Annaswamy and Gantz, Ira and Crutchlow, Michael and Flynn, Heather and Xu, Lianzhe and Rodgers, Anthony J and Krishnan, Radha and Rizk, Matthew L and Hu, Shuai and Kaufman, Keith D and Engel, Samuel S and MK‐3655 P001 Study Group, MK‐3655 P001 Study Group},
title = {Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70038}
}
EUVIMED